

Gerald P. Murphy et al.
Application No.: 09/016,737
Page 2

PATENT

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of the claims in this application.

1 23. (Currently Amended) A composition comprising an isolated cell
2 population exposed *in vitro* to a soluble prostate antigen, the cell population having an
3 increased number of human dendritic cells competent and able to activate T cells specific
4 to a the prostate antigen as compared to an isolated cell population comprising the same
5 number of cells that has not been exposed *in vitro* to the prostate antigen.

1 24. (Currently Amended) The composition according to claim 23, in
2 which the prostate antigen is a lysate of LNCaP cells, a membrane preparation of LNCaP
3 cells, a lysate of prostate tumor cells from a prostate cancer patient, a membrane
4 preparation of prostate tumor cells from a prostate cancer patient, isolated prostate
5 specific membrane antigen (PSMA), purified prostate specific membrane antigen
6 (PSMA), a peptide having the amino acid sequence LLHETDSAV (SEQ ID NO: 1), a
7 peptide having the amino acid sequence ALFDIESKV (SEQ ID NO: 2), a peptide having
8 the amino acid sequence XL(orM)XXXXXV(orL) (SEQ ID NO: 3), where X represents
9 any amino acid, purified prostate specific antigen (PSA), or a purified prostate mucin
10 antigen recognized by monoclonal antibody PD41.

1 26. (Original) The composition according to claim 23, in which the
2 dendritic cells are extended life span dendritic cells.

1 28. (Previously Amended) The composition according to claim 23, in
2 which the dendritic cells have been cryopreserved prior to exposure *in vitro* to the
3 prostate antigen, wherein said dendritic cells retain the ability to take up and present
4 antigen.

Gerald P. Murphy et al.
Application No.: 09/016,737
Page 3

PATENT

F3

1 29. (Currently Amended) The composition according to claim 28, in
2 which the prostate antigen is a lysate of LNCaP cells, a membrane preparation of LNCaP
3 cells, a lysate of prostate tumor cells from a prostate cancer patient, a membrane
4 preparation of prostate tumor cells from a prostate cancer patient, isolated prostate
5 specific membrane antigen (PSMA), purified prostate specific membrane antigen
6 (PSMA), a peptide having the amino acid sequence LLHETDSAV (SEQ. ID. NO. 1), a
7 peptide having the amino acid sequence ALFDIESKV (SEQ. ID. NO. 2), a peptide
8 having the amino acid sequence XL(orM)XXXXX(orL) (SEQ. ID. NO. 3), where X
9 represents any amino acid, purified prostate specific antigen (PSA), or a purified prostate
10 mucin antigen recognized by monoclonal antibody PD41.

1 30. (Previously Amended) The composition according to claim 28, in
2 which the dendritic cells are extended life dendritic cells.

F4

1 31. (Currently Amended) The composition according to claim 23
2 comprising a cell population having at least 20 fold more dendritic cells competent to
3 and able to activate ~~prostate antigen specific~~ T cells specific to the prostate antigen as
4 compared to an isolated cell population directly isolated from peripheral blood
5 comprising the same number of cells that has not been exposed *in vitro* to the prostate
6 antigen.

1 32. (Previously Amended) The composition according to claim 23,
2 wherein the human dendritic cells are immature dendritic cells.

1 33. (Previously Added) The composition according to claim 23,
2 wherein the T cells are CD4⁺.

1 34. (Previously Added) The composition according to claim 23,
2 wherein the T cells are CD8⁺.

Gerald P. Murphy et al.
Application No.: 09/016,737
Page 4

PATENT

1 35. (Previously Added) The composition according to claim 23,
2 wherein the dendritic cells are isolated from a prostate cancer patient.

1 36. (Previously Added) The composition according to claim 23,
2 wherein the dendritic cells are isolated from a normal individual.

FS 1 37. (Currently Added) The composition according to claim 36,
2 wherein the dendritic cells are HLA-matched for the a recipient.